What ICD-10-CM code should be used to justify a pharmacogenomic (PGX) test that determines which medications the patient's DNA will metabolize?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

ICD-10-CM Code for Pharmacogenomic Testing

The most appropriate ICD-10-CM code to justify pharmacogenomic (PGX) testing is Z13.89 (Encounter for screening for other disorder) or Z80.0-Z84.89 (Family history codes) when applicable, though the specific code selection depends heavily on the clinical indication and payer requirements.

Understanding the Coding Challenge

The provided evidence does not directly address ICD-10-CM coding for pharmacogenomic testing 1. The ACMG guidelines focus on laboratory standards for performing and reporting PGX tests, not billing justification 1. This reflects a broader challenge in clinical practice: PGX testing exists in a gray zone where traditional diagnosis-based coding doesn't align well with preventive genomic testing.

Practical Coding Approach

Primary Options:

For preemptive/screening PGX testing:

  • Z13.89 - Encounter for screening for other disorder
  • Z79.899 - Other long-term (current) drug therapy (if patient is already on medications)

For reactive testing (medication-specific):

  • Use the underlying condition being treated (e.g., F32.9 for depression if testing CYP2D6 for antidepressants)
  • Z88.8 - Allergy status to other drugs, medicaments and biological substances (for adverse drug reaction history)
  • Z91.89 - Other specified personal risk factors (for history of medication intolerance)

For family history considerations:

  • Z80-Z84 codes - Family history codes when relevant genetic predisposition exists

Clinical Context Matters

The ACMG guidelines emphasize that PGX testing examines genetic variants affecting drug metabolism, with the goal of preventing therapeutic failure, side effects, or adverse events 1. This preventive nature creates coding challenges because:

  • Traditional ICD-10 codes require a diagnosis, but PGX testing is often performed before problems occur
  • Insurance coverage varies widely - some payers require specific medication prescriptions or documented adverse reactions
  • The test itself doesn't treat a disease - it guides future prescribing decisions

Payer-Specific Considerations

Critical caveat: Insurance coverage for PGX testing remains inconsistent. Many payers require:

  • Documentation of prior adverse drug reactions
  • Specific medication prescriptions (e.g., testing CYP2C19 only when prescribing clopidogrel)
  • Failed trials of standard medications
  • Pre-authorization with specific diagnosis codes

Check individual payer policies before ordering, as they may mandate specific ICD-10 codes or clinical scenarios for coverage.

Gene-Specific Coding Strategy

When testing is medication-specific (reactive testing), code based on the condition being treated:

  • CYP2D6 for antidepressants: Use depression diagnosis (F32.x, F33.x)
  • CYP2C19 for clopidogrel: Use coronary artery disease (I25.10) or acute coronary syndrome codes
  • TPMT/NUDT15 for thiopurines: Use the underlying cancer or autoimmune condition
  • HLA-B*57:01 for abacavir: Use HIV diagnosis (B20)

Documentation Requirements

To support medical necessity, document:

  • Specific medications being considered or currently prescribed
  • History of adverse drug reactions or therapeutic failures (if applicable)
  • Clinical rationale for testing (e.g., "Patient requires antidepressant therapy; PGX testing to guide CYP2D6-metabolized medication selection")
  • How results will impact treatment decisions

The Reality of Preemptive Testing

The evidence shows preemptive PGX testing (testing before medication need) is more efficient than reactive single-gene testing 2. However, coding for preemptive testing is particularly challenging because no specific medication or condition may exist yet. In these cases:

  • Z13.89 is your best option for truly preemptive panels
  • Consider adding Z79.899 if patient takes any chronic medications
  • Some practices use Z80.0 (family history of malignant neoplasm) or other family history codes when applicable

Common Pitfalls to Avoid

  • Don't use R codes (symptoms) unless truly applicable - they're often rejected for genetic testing
  • Avoid Z codes that imply genetic disease testing (Z15.x series) - these are for hereditary disease risk, not pharmacogenomics
  • Don't code for conditions the patient doesn't have just to justify testing
  • Never use unspecified codes (e.g., Z13.9) when more specific options exist

The bottom line: ICD-10-CM coding for PGX testing requires matching the clinical scenario to the most defensible code, with Z13.89 serving as the fallback for preemptive testing when no specific condition or medication exists yet.

References

2
Guideline

advancing pharmacogenomics from single-gene to preemptive testing.

Annual Review of Genomics and Human Genetics, 2022

Related Questions

What are the ICD‑10‑CM diagnosis codes for Attention‑Deficit/Hyperactivity Disorder (ADHD) and the ICD‑9‑CM code?
What is the appropriate ICD‑10‑CM code for attention‑deficit/hyperactivity disorder in an adult with racing thoughts?
What ICD‑10‑CM diagnostic codes, other than screening codes, can be used for a Pap smear performed as part of the pre‑egg donation work‑up in a 19‑year‑old woman?
What ICD-10-CM diagnosis codes correspond to social isolation?
Which CPT (Current Procedural Terminology) codes and ICD‑10‑CM (International Classification of Diseases, 10th Revision, Clinical Modification) codes should be assigned for an established‑patient office visit with medication management and brief counseling (≈15 minutes), and for a separate 45‑minute individual psychotherapy session, given diagnoses of mild major depressive disorder and generalized anxiety disorder, and counseling?
What does a urine microalbumin-to-creatinine ratio of 1055 mg/g indicate and how should it be managed?
What is the recommended management for a HER2‑positive tumor?
What is the appropriate work‑up and acute management for an adult female with new‑onset migraine presenting with photophobia, bilateral eye pressure, nausea, vomiting, visual disturbances, a normal non‑contrast head CT, and a history of Ehlers‑Danlos syndrome, chronic gum bleeding, prior mold exposure, an NTHFR gene variant, and recent use of CytoQuil and Axia Ease supplements?
What is the recommended next-line therapy for a patient with gastroesophageal junction adenocarcinoma that is HER2‑positive (3+), expresses claudin 30%, after poor tolerance of FOLFOX (folinic acid, fluorouracil, oxaliplatin) plus trastuzumab (Herceptin)?
What is the most likely diagnosis in a 20-year-old male presenting with hyperventilation, tachycardia, inability to move his entire body, and a persistent unblinking stare?
Is an abdominal MRI indicated for a patient presenting with epigastric pain?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.